Minimal Residual Disease MRD Monitoring for B-Cell Chronic Lymphocytic Leukemia Test
Understanding Minimal Residual Disease Monitoring
Minimal Residual Disease (MRD) monitoring represents a revolutionary approach in cancer management, specifically designed for patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL). This highly sensitive diagnostic technique detects and quantifies the small number of cancer cells that may remain in the body after treatment, even when traditional methods show complete remission. The ability to identify these residual cells provides invaluable insights into treatment effectiveness and helps predict the likelihood of disease recurrence.
What Does the MRD Monitoring Test Measure?
Our advanced MRD monitoring test utilizes sophisticated flow cytometry technology to:
- Detect and quantify residual B-CLL cells in bone marrow and peripheral blood samples
- Identify as few as one cancer cell among 10,000 normal cells (sensitivity of 0.01%)
- Monitor changes in leukemia cell populations over time
- Assess treatment response and effectiveness
- Provide early detection of disease progression or recurrence
Who Should Consider MRD Monitoring?
This specialized test is recommended for:
- Patients diagnosed with B-Cell Chronic Lymphocytic Leukemia undergoing treatment
- Individuals who have completed chemotherapy or targeted therapy regimens
- Patients in clinical remission who require ongoing monitoring
- Those participating in clinical trials for new leukemia treatments
- Individuals with a history of B-CLL requiring long-term surveillance
Key Clinical Indications Include:
- Monitoring treatment response during therapy
- Assessing depth of remission after treatment completion
- Early detection of molecular relapse before clinical symptoms appear
- Guiding decisions about treatment intensification or modification
- Evaluating the need for additional therapeutic interventions
Benefits of MRD Monitoring for B-CLL Patients
Choosing MRD monitoring provides numerous advantages for comprehensive leukemia management:
- Early Detection: Identify disease recurrence months before clinical symptoms appear
- Personalized Treatment: Guide therapy decisions based on individual response patterns
- Improved Outcomes: Enable timely intervention to prevent full relapse
- Reduced Anxiety: Provide objective data about treatment effectiveness
- Cost-Effective Care: Potentially reduce long-term healthcare costs through early intervention
- Enhanced Quality of Life: Support informed decisions about treatment intensity and duration
Understanding Your Test Results
Your MRD monitoring results will provide critical information about your leukemia status:
MRD-Negative Results
An MRD-negative result indicates that no detectable leukemia cells were found at the test’s sensitivity level. This typically suggests:
- Excellent treatment response
- Lower risk of early relapse
- Potential for longer remission duration
- May support consideration of treatment de-escalation in some cases
MRD-Positive Results
Detection of residual leukemia cells provides important clinical information:
- Indicates persistent disease despite treatment
- Higher risk of clinical relapse
- May warrant consideration of treatment modification
- Helps guide decisions about additional therapy
Quantitative MRD Levels
The test provides precise quantification of residual disease, allowing for:
- Monitoring trends over multiple time points
- Assessing response to different treatment phases
- Comparing results with established prognostic thresholds
- Informing decisions about treatment duration and intensity
Test Details and Pricing
| Test Component | Details |
|---|---|
| Test Name | Minimal Residual Disease MRD Monitoring for B-Cell Chronic Lymphocytic Leukemia Test |
| Regular Price | $626 USD |
| Discount Price | $426 USD |
| Turnaround Time | Sample Daily by 11 am; Report 3 Working Days |
| Sample Type | 3 mL Bone Marrow in Green Top (Sodium Heparin) tube AND 4 mL whole blood in 2 Green Top (Sodium Heparin) tubes |
| Methodology | Flow Cytometry |
| Department | Flow Cytometry |
Sample Collection Requirements
Proper sample collection is crucial for accurate MRD monitoring results:
- Bone Marrow: 3 mL (1 mL minimum) first pull aspirate in Green Top Sodium Heparin tube
- Peripheral Blood: 4 mL (3 mL minimum) whole blood in 2 Green Top Sodium Heparin tubes
- Transport: Ship immediately at 18-22°C or 2-8°C – DO NOT FREEZE
- Required Documentation: Sample time point, previous immunophenotype report, clinical history, therapy details, and collection timing
Why Choose GGC DNA for Your MRD Monitoring?
GGC DNA stands as a leader in genetic and molecular diagnostics with:
- State-of-the-art flow cytometry facilities across the United States
- Expert hematologists and oncologists overseeing test interpretation
- Rapid 3-working-day turnaround for timely clinical decisions
- Comprehensive support for patients and healthcare providers
- Convenient locations in all major cities including New York, Los Angeles, Chicago, Houston, and Phoenix
Take Control of Your Leukemia Management Today
Don’t leave your leukemia monitoring to chance. Our MRD monitoring test provides the precision and sensitivity needed for optimal disease management. With locations across the USA and expert clinical support, GGC DNA makes advanced leukemia monitoring accessible and reliable.
Book your Minimal Residual Disease MRD Monitoring test today at our special price of $426 USD!
Call or WhatsApp us at +1(267) 388-9828 to schedule your test or speak with our genetic counseling team. Early detection and precise monitoring can make all the difference in your leukemia journey.
